New Opportunity For CER As Placebo Trials Show Shrinking Drug Efficacy Margins – Health Affairs
Executive Summary
Authors of a Health Affairs article find the effect of active drugs versus placebo has declined in controlled trials over time, suggesting to them that more attention should be focused on understanding the clinical value of existing treatments, including establishing equivalence of efficacy and focusing on differences in safety, cost and tolerability.
You may also be interested in...
Drug Development Needs “Clean-Slate Think” To Involve Patients All Along The Way – Pfizer’s Lewis-Hall
Drug companies and other stakeholders should collaborate on developing a “clear framework” for patient engagement, Freda Lewis-Hall says at ISPOR.
Comparative Evidence Needs Earlier Consideration In Drug Development Process – Novartis Exec
As comparative effectiveness research grows in importance, drug manufacturers need to factor it, as well as payer evidence needs, into product development decisions, Novartis Head of Comparative Effectiveness Research and Communications Amy Rudolph says.
FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.